Catalent Inc. (CTLT) is scheduled to announce Q3 2023 earnings on Monday, 12 June 2023, before market open. Wallstreet estimates an EPS of $-0.07 and a revenue of $952.66 M in the upcoming results. Historically, Catalent Inc. beated EPS estimates 64% of the times.
About Catalent Inc.
Catalent, Inc. develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. It operates through four segments: Biologics and Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The company serves pharmaceutical, biotechnology, consumer health companies; and companies in other healthcare market segments such as animal health and medical devices.